Transforming Chronic Wound Care
Every year ~100 million people suffer from chronic wounds worldwide
Despite many innovations in wound care over the years, chronic wound healing rates have barely changed
Lack of easy-to-use, effective treatments to debride chronic wounds and return them to healing leaves patients suffering and is a huge burden on healthcare systems
Selected for the Innovate UK & TMC Innovation Accelerator Program, in partnership with Texas Medical Center, in 2024
Awarded the Biomedical Catalyst Grant by Innovate UK, the UK's innovation agency in 2024
Awarded EIC Accelerator Grant by the European Innovation Council in 2023
Selected as a 2023 Life Sciences Innovator by UK Department for Business and Trade
1st place in the Biotech Category at EIT Health Catapult (European Institute of Innovation & Technology) in 2022
Winner of the 2019 URGO Mentorship Program
Industry Recognition
Latest News
Change is needed in current health systems – patients, practitioners, and regulators across the industry are in urgent need of high-impact innovations
in chronic wound care
SOLASCURE IS AT THE FOREFRONT OF ADDRESSING THIS DEMAND
Aurase Wound Gel, a hydrogel containing the proteolytic enzyme Tarumase, is an enzymatic debrider that aims to eliminate slough, disrupt bacterial biofilm leading to reduced bioburden, and promote wound bed preparation and healing. Tarumase is a highly-specific fibrinolytic enzyme cloned from maggot saliva, perfectly optimised by evolution for wound bed preparation.